Suzanne McGurn, President and CEO of CADTH, is pleased to announce the appointment of new members of the CADTH Canadian Drug Expert Committee (CDEC) and the CADTH pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC), as well as a new chair and new members of the Health Technology Expert Review Panel (HTERP).
The following individuals have been appointed as members of CDEC:
The following individuals have been appointed as members of pERC:
Dr. Leslie Anne Campbell, the inaugural Sobey Family Chair in Child and Adolescent Mental Health Outcomes and an Associate Professor in the Department of Community Health and Epidemiology and School of Nursing at Dalhousie University, becomes Chair of HTERP for a 2-year term. Dr. Campbell brings to the role a significant background in clinical practice, epidemiology, and health services research.
In addition, the following individuals have been appointed as members of HTERP:
Biographies of CDEC, pERC, and HTERP members are available on the CADTH website.
Ms. McGurn would like to thank the following committee members who concluded their terms of office: Dr. Ahmed Bayoumi (CDEC member), Dr. Bruce Carleton (CDEC member), Dr. Kelvin Chan (pERC member), Dr. Avram Denberg (pERC member), Dr. Hillary Jaeger (Chair of HTERP), Dr. Christine Kennedy (pERC member), Allen Lefebvre (CDEC member), Valerie McDonald (pERC member), Jeremy Petch (HTERP member), Yvonne Shevchuk (CDEC member), Tonya Somerton (HTERP member), and Dr. Adil Virani (CDEC member).
CADTH committees provide expert advice and recommendations to CADTH. Members are selected from across Canada based on their clinical and policy expertise relating to the assessment of health technologies.
CDEC is an appointed, pan-Canadian advisory body composed of individuals with expertise in drug therapy, drug evaluation, and drug utilization as well as patient members. CDEC makes recommendations to each of the participating federal, provincial, and territorial publicly funded drug plans regarding reimbursements on their formularies. It also makes recommendations related to the identification, evaluation, and promotion of optimal drug prescribing and use in Canada.
pERC is an appointed, pan-Canadian advisory body composed of individuals with expertise in drug therapy, drug evaluation, and drug utilization as well as patient members. pERC assesses the clinical evidence and cost-effectiveness of cancer drugs to make recommendations to the provinces and territories to help guide their drug funding decisions.
HTERP is an advisory body convened to develop guidance and/or recommendations on non-drug health technologies. The panel provides advice and non-binding recommendations to help decision-makers make informed decisions about the best use of non-pharmaceutical health technologies, such as medical devices, surgical procedures, diagnostic tests, and other non-pharmaceutical interventions.